Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

435 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Management of anaemia in oncohaematological patients treated with biosimilar epoetin alfa: results of an Italian observational, retrospective study.
Rosti G, Petrini M, Bosi A, Galieni P, Bernardi D, Giglio G, Dorotea L, Falini B, Scelzi E, Veltri E, Castelli R, Longagnani C, Raggi T, Simonetti F. Rosti G, et al. Among authors: bosi a. Ther Adv Med Oncol. 2017 Jan;9(1):22-32. doi: 10.1177/1758834016670554. Epub 2016 Oct 22. Ther Adv Med Oncol. 2017. PMID: 28203295 Free PMC article.
Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML.
Bassan R, Intermesoli T, Masciulli A, Pavoni C, Boschini C, Gianfaldoni G, Marmont F, Cavattoni I, Mattei D, Terruzzi E, De Paoli L, Cattaneo C, Borlenghi E, Ciceri F, Bernardi M, Scattolin AM, Todisco E, Campiotti L, Corradini P, Cortelezzi A, Ferrero D, Zanghì P, Oldani E, Spinelli O, Audisio E, Cortelazzo S, Bosi A, Falini B, Pogliani EM, Rambaldi A. Bassan R, et al. Among authors: bosi a. Blood Adv. 2019 Apr 9;3(7):1103-1117. doi: 10.1182/bloodadvances.2018026625. Blood Adv. 2019. PMID: 30948365 Free PMC article. Clinical Trial.
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients.
Bocchia M, Galimberti S, Aprile L, Sicuranza A, Gozzini A, Santilli F, Abruzzese E, Baratè C, Scappini B, Fontanelli G, Trawinska MM, Defina M, Gozzetti A, Bosi A, Petrini M, Puccetti L. Bocchia M, et al. Among authors: bosi a. Oncotarget. 2016 Nov 1;7(44):72311-72321. doi: 10.18632/oncotarget.11100. Oncotarget. 2016. PMID: 27527867 Free PMC article.
High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation as Adjuvant Treatment in High-Risk Breast Cancer: Data from the European Group for Blood and Marrow Transplantation Registry.
Martino M, Lanza F, Pavesi L, Öztürk M, Blaise D, Leno Núñez R, Schouten HC, Bosi A, De Giorgi U, Generali D, Rosti G, Necchi A, Ravelli A, Bengala C, Badoglio M, Pedrazzoli P, Bregni M; European Group for Blood and Marrow Transplantation Solid Tumor Working Party. Martino M, et al. Among authors: bosi a. Biol Blood Marrow Transplant. 2016 Mar;22(3):475-81. doi: 10.1016/j.bbmt.2015.12.011. Epub 2015 Dec 23. Biol Blood Marrow Transplant. 2016. PMID: 26723932 Free article.
Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients.
Scappini B, Gianfaldoni G, Caracciolo F, Mannelli F, Biagiotti C, Romani C, Pogliani EM, Simonetti F, Borin L, Fanci R, Cutini I, Longo G, Susini MC, Angelucci E, Bosi A. Scappini B, et al. Among authors: bosi a. Am J Hematol. 2012 Dec;87(12):1047-51. doi: 10.1002/ajh.23308. Epub 2012 Aug 1. Am J Hematol. 2012. PMID: 23151979 Free article. Clinical Trial.
The Combination of Rituximab and Bendamustine as First-Line Treatment Is Highly Effective in the Eradicating Minimal Residual Disease in Follicular Lymphoma: An Italian Retrospective Study.
Galimberti S, Ciabatti E, Ercolano G, Grassi S, Guerrini F, Cecconi N, Rousseau M, Cervetti G, Mazziotta F, Iovino L, Falzetti F, Falcinelli F, Bosi A, Rigacci L, Kovalchuk S, Vallisa D, Macchia L, Ciancia E, Petrini M. Galimberti S, et al. Among authors: bosi a. Front Pharmacol. 2017 Jun 29;8:413. doi: 10.3389/fphar.2017.00413. eCollection 2017. Front Pharmacol. 2017. PMID: 28706485 Free PMC article.
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia.
Galimberti S, Bucelli C, Arrigoni E, Baratè C, Grassi S, Ricci F, Guerrini F, Ciabatti E, Fava C, D'Avolio A, Fontanelli G, Cambrin GR, Isidori A, Loscocco F, Caocci G, Greco M, Bocchia M, Aprile L, Gozzini A, Scappini B, Cattaneo D, Scortechini AR, La Nasa G, Bosi A, Leoni P, Danesi R, Saglio G, Visani G, Cortelezzi A, Petrini M, Iurlo A, Di Paolo A. Galimberti S, et al. Among authors: bosi a. Oncotarget. 2017 Sep 30;8(50):88021-88033. doi: 10.18632/oncotarget.21406. eCollection 2017 Oct 20. Oncotarget. 2017. PMID: 29152138 Free PMC article.
Anaemia characterises patients with myelofibrosis harbouring Mpl mutation.
Guglielmelli P, Pancrazzi A, Bergamaschi G, Rosti V, Villani L, Antonioli E, Bosi A, Barosi G, Vannucchi AM; GIMEMA--Italian Registry of Myelofibrosis; MPD Research Consortium. Guglielmelli P, et al. Among authors: bosi a. Br J Haematol. 2007 May;137(3):244-7. doi: 10.1111/j.1365-2141.2007.06565.x. Br J Haematol. 2007. PMID: 17408465 Free article.
Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.
Foà R, Bassan R, Vitale A, Elia L, Piciocchi A, Puzzolo MC, Canichella M, Viero P, Ferrara F, Lunghi M, Fabbiano F, Bonifacio M, Fracchiolla N, Di Bartolomeo P, Mancino A, De Propris MS, Vignetti M, Guarini A, Rambaldi A, Chiaretti S; GIMEMA Investigators. Foà R, et al. N Engl J Med. 2020 Oct 22;383(17):1613-1623. doi: 10.1056/NEJMoa2016272. N Engl J Med. 2020. PMID: 33085860 Clinical Trial.
435 results